A bullish thesis for the consumer health company was presented by Danny Green. The stock was trading at $18.66 as of February 19th. Its forward price-to-earnings ratio is 17.01, which is notably lower than its trailing P/E of 24.93, suggesting expectations for improved earnings. The company is newly independent following a corporate spin-off. The article summarizing this case is the primary piece of relevant news.